Identification and validation of microtubule depolymerizing agent, CYT997, as a potential drug candidate for hepatocellular carcinoma.

Faiz Ahmad¹, Li Ma¹, Wei Wei¹, Yi Liu¹, Isaac Hakim², Aaron Daugherty², Sana Mujahid², Andrew A Radin², Mei-Sze Chua¹, Samuel So¹

¹Asian Liver Center, Department of Surgery, School of Medicine, Stanford, California, USA.

²Aria Pharmaceuticals, Palo Alto, California, USA.

PubMed PMC DOI PDF

Abstract

BACKGROUND AND AIMS: Hepatocellular carcinoma (HCC) is a typically fatal malignancy with limited treatment options and poor survival rates, despite recent FDA approvals of newer treatment options. We aim to address this unmet need by using a proprietary computational drug discovery platform that identifies drug candidates with the potential to advance rapidly and successfully through preclinical s…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.